Edition:
United States

Galena Biopharma Inc (GALE.PH)

GALE.PH on Philadelphia Stock Exchange

0.57USD
26 Jul 2017
Change (% chg)

$-0.01 (-1.38%)
Prev Close
$0.57
Open
$0.57
Day's High
$0.57
Day's Low
$0.57
Volume
100
Avg. Vol
1,825
52-wk High
$10.00
52-wk Low
$0.53

Latest Key Developments (Source: Significant Developments)

Galena Biopharma updates on exploring strategic options
Wednesday, 12 Jul 2017 06:30am EDT 

July 12 (Reuters) - Galena Biopharma Inc -:Galena Biopharma provides corporate update.Galena Biopharma-‍with support of Canaccord Genuity, had interactions with cos to explore options for monetizing some/all clinical development programs​.Galena Biopharma - has had extensive interactions with numerous cos to explore options for monetizing some,all of its clinical development programs​.Galena Biopharma-‍exploring options for monetizing some/all of clinical development programs through license or sale of assets, and/or sale, merger among others.Galena Biopharma Inc - ‍management has significantly reduced staffing levels and certain operational expenses to preserve cash​.Galena Biopharma Inc - ‍work remains ongoing to advance its two core clinical programs, gale-401 and neuvax​.Galena Biopharma Inc says has ‍had initial interest in potential transactions from a number of companies​.  Full Article

Galena Biopharma Q1 loss per share $0.45
Wednesday, 10 May 2017 04:30pm EDT 

May 10 (Reuters) - Galena Biopharma Inc ::Galena Biopharma reports first quarter 2017 financial results.Q1 loss per share $0.09 from continuing operations.Q1 loss per share $0.45.  Full Article

Galena Biopharma presents positive interim safety data on NeuVax clinical trial
Tuesday, 4 Apr 2017 07:05am EDT 

Galena Biopharma Inc : Galena Biopharma presents positive interim safety data on the neuva (nelipepimut-s) clinical trial in combination with trastuzumab in high-risk HER2 3+ patients at the AACR annual meeting 2017 .Galena Biopharma Inc says in trial, there were no significant clinicopathologic differences between groups.  Full Article

Galena presents positive early-stage data on GALE-301
Friday, 17 Mar 2017 07:05am EDT 

Galena Biopharma Inc : Galena biopharma presents positive final gale-301 (e39) phase 1/2a clinical trial data . Galena biopharma - patients with primary disease who received 1000mcg dose appear to maintain a statistically significant benefit while those with recurrent disease were not .Galena biopharma inc - final data from early stage clinical trial demonstrates that gale-301 is well tolerated.  Full Article

Galena Biopharma evaluates strategic alternatives
Wednesday, 15 Mar 2017 04:15pm EDT 

Galena Biopharma Inc : Galena Biopharma reports fourth quarter and year end 2016 financial results and provides a corporate update . Q4 loss per share $0.49 .Galena Biopharma - working closely with advisors to evaluate strategic alternatives, including monetizing assets, sale of co, a business combination.  Full Article

Galena Biopharma engages Canaccord Genuity to advise on strategic alternatives
Thursday, 9 Mar 2017 07:05am EST 

Galena Biopharma Inc : Galena biopharma engages Canaccord Genuity to advise on strategic alternatives . Galena biopharma - potential strategic alternatives may include a sale of company, a business combination, a merger or reverse merger with another party .Galena biopharma - potential strategic alternatives may include continuing to advance clinical programs as stand-alone entity, disposition of assets.  Full Article

CVI Investments reports 9.3 pct passive stake in Galena Biopharma
Friday, 17 Feb 2017 08:56am EST 

Galena Biopharma Inc :CVI Investmentsreports 9.3 percent passive stake in Galena Biopharma Inc as of feb 8 - SEC filing.  Full Article

Galena Biopharma announces pricing of public offering of common stock and warrants
Wednesday, 8 Feb 2017 08:30am EST 

Galena Biopharma Inc : Galena Biopharma announces pricing of public offering of common stock and warrants . Galena Biopharma Inc- pricing of an underwritten public offering of units with anticipated gross proceeds of $17 mln .Galena Biopharma - offering each unit that consists of 1 full share of stock, warrant to purchase 1 share of common stock, is priced at $1.00 per unit.  Full Article

Galena Biopharma announces proposed public offering of common stock and warrants
Tuesday, 7 Feb 2017 04:10pm EST 

Galena Biopharma Inc :Galena Biopharma announces proposed public offering of common stock and warrants.  Full Article

Galena biopharma reports positive outcome from the data safety monitoring board on the two Neuvax trials
Monday, 6 Feb 2017 07:05am EST 

Galena Biopharma Inc : Galena Biopharma reports positive outcome from the data safety monitoring board on the two neuvax (nelipepimut-s) clinical trials in combination with trastuzumab . Interim efficacy analysis for low-to-intermediate (her2 1+/2+) trial now expected by end of 2017 . Says interim efficacy analysis for low-to-intermediate (her2 1+/2+) trial now expected by end of 2017 . Both combination trials are deemed not futile and data safety monitoring board recommends that both trials continue . DSMB expects to perform interim efficacy analysis near end of 2017 . Says data safety monitoring board reported that there are no safety concerns with either trial and neither was found to be futile .Phase 2 trial showed agent is well tolerated with no increased cardiotoxicity associated with giving Neuvax with Trastuzumab.  Full Article

BRIEF-Galena Biopharma updates on exploring strategic options

* Galena Biopharma-‍with support of Canaccord Genuity, had interactions with cos to explore options for monetizing some/all clinical development programs​